ArmaGen Technologies, a US-based life sciences company known as Neurogene Technologies until 2004, has raised $17m in its series A round from four corporations.
Boehringer Ingelheim Venture Fund, the corporate venturing unit of the eponymous Germany-based healthcare company, led the A round syndicate, which also included drug peers Shire and Takeda’s venturing units, and Japan-based financial conglomerate Mitsui’s Global Investment division.
William Pardridge, founder and chief scientific officer of ArmaGen and professor of medicine and director of the Blood Brain Barrier Research Laboratory at University of California, Los Angeles, (UCLA), where he has worked since 1978, said: “The ArmaGen investor syndicate is a unique group of big pharma[ceutical companie]s each with their own global impact. This is the first time such a diverse group from the pharmaceutical industry has come together to finance technology in the blood-brain barrier.”
Pardridge formed ArmaGen in 2004, and has financed the company to date…
